Anti-Phosphatidylserine Antibodies in Acute Myocardial Infarction

Abstract

Acute Myocardial Infarction (AMI) is the combined result of environmental factors and personal predispositions. Many factors play a role in AMI including anti-Phospholipid (aPL) antibodies, that may act in the induction of immunological response leading to the development of AMI. AntiPhosphatidylserine (PS) antibody is detected in various diseases like rheumatoid arthritis, systemic lupus erythematosus and anti-phospholipid antibody syndrome. The study of anti-PS antibody in AMI might shed light on etiologic mechanisms in the pathogenesis of acute coronary syndromes. This study was conducted to evaluate whether prevalence of anti-PS antibodies, in patients who had AMI and to analyze their relationship with traditional cardiovascular risk factors. The prevalence of anti-PS IgG and IgM in a well characterized group of patients with AMI as a case group and in age and sex matched healthy subjects as control group. Sera from two groups were tested to evaluate the presence of IgG and IgM isotypes to anti-PS by ELISA method. The frequencies of positive test for anti-PS IgG were 26.70 and 8.90% among patients and controls respectively with significant difference (p = 0.003). The anti-PS IgM frequencies were 12.20 and 1.10% in patients and the controls, with significant difference (p = 0.005). The findings of this study suggest that anti-PS antibodies seemed to play a role in AMI, independent risk factors for AMI, which may represent a link between autoimmunity and atherosclerosis in patients with AMI. Further studies with bigger sample size including patients with AMI and healthy people are recommended to explore the exact role of anti-PS antibodies in AMI.

The Presence of Anti-Phosphatidylethanolamine Antibodies in Acute Myocardial Infarction

“…The results of this study in parallel with the data from other studies about oyher anti-phospholipid antibodies (Shojaie et al, 2011;Jafarzadeh et al, 2011;Urbanus et al, 2009;Jahromi et al, 2013;Sanmarco et al, 2007) support the potential important role of aPL antibodies in AMI.…”

“…These results are in accordance with the results of previous studies (Shojaie et al, 2011;Jahromi et al, 2010c;2013).…”

“…Other aPLs antibodies have been reported to have association with CAD and AMI (Shojaie et al, 2011;Jafarzadeh et al, 2011;Greco et al, 2010). The result of present study and other researches (Shojaie et al, 2011;Jafarzadeh et al, 2011;Urbanus et al, 2009;Jahromi et al, 2013;Sanmarco et al, 2007) are consistent with current concepts on the immune pathogenesis of atherosclerosis. However, the precise mechanisms of involvement of aPEA antibodies in the pathogenesis of AMI remain to be determined.…”

“…Factors such as low serum adiponectin (Shojaie et al, 2009a) and low annexin V levels (Shojaie et al, 2009b) and infectious diseases such as Mycoplasma pneumonia (Pourahmad et al, 2009) are a part of involving factors in AMI. It has been demonstrated that the immunopathological such as anti-beta2 glycoprotein-I antibody (Shojaie et al, 2011), Anti-Phosphatidylserine antibodies (Jahromi et al, 2013) and Inflammatory processes (Jahromi et al, 2010a) have important roles in the initiation and development of AMI.…”

A Comparative Study of Anti-Phosphatidyl Inositole Antibodies in Patients With Myocardial Infarction and Healthy Subjects

“…Antiphospholipid Antibodies (Abs) (aPL) in addition to repeated miscarriages and pregnancy complications (Jahromi et al, 2010c;El-Deen, 2013) participate in cardiovascular diseases (Jahromi et al, 2013a;Shojaie and Jahromi, 2011;Jahromi et al, 2013b). However their pathogenic mechanisms are still matter of investigation.…”